• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Alnylam Pharmaceuticals (NQ: ALNY )

    237.83 +1.13 (+0.48%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 878,604
    Open 238.16
    Bid (Size) 238.00 (1)
    Ask (Size) 266.00 (1)
    Prev. Close 236.70
    Today's Range 235.30 - 240.91
    52wk Range 141.97 - 263.73
    Shares Outstanding 118,847,693
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    $100 Invested In This Stock 20 Years Ago Would Be Worth $4,100 Today
    Via Benzinga
    Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire

    Performance

    YTD
    +22.01%
    +22.01%
    1 Month
    +43.53%
    +43.53%
    3 Month
    +63.13%
    +63.13%
    6 Month
    +29.31%
    +29.31%
    1 Year
    +23.66%
    +23.66%

    More News

    Read More
    Alnylam Stock Is a Blockbuster Biopharma In the Making
    Via InvestorPlace
    Peering Into Alnylam Pharmaceuticals's Recent Short Interest
    Via Benzinga
    35% Surge Just the Beginning? Alnylam’s Stock Poised for Massive Gains on Heart Drug Success.
    Via InvestorPlace
    Peering Into Alnylam Pharmaceuticals's Recent Short Interest
    Via Benzinga
    7 Cheap Biotech Stocks With Major Upside Potential
    Via InvestorPlace
    Down 55%, Is Pfizer a Good Dividend Stock to Buy on the Dip?
    Via The Motley Fool
    EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
    Via Benzinga
    Topics ETFs
    $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
    Via Benzinga
    Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows
    Via Benzinga
    Topics ETFs
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Rivian Automotive And Carvana Were Among The 10 Biggest Large Cap Gainers Last Week (June 23-June 29): Are These In Your Portfolio?
    Via Benzinga
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Nvidia, Affirm Holdings, Carnival Corp, Alnylam Pharmaceuticals, Tesla: Why These 5 Stocks Are On Investors' Radars Today
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Semiconductor, Nvidia Woes Deepen; Nasdaq 100 Slips, Dow Rallies; Bitcoin Sinks To $60,400: What's Driving Markets Monday?
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears
    Via InvestorPlace
    Exposures Product Safety
    Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success
    Via InvestorPlace
    Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
    Via Benzinga
    Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug
    Via Investor's Business Daily
    RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
    From Alnylam Pharmaceuticals, Inc.
    Via Business Wire
    Masters In Trading - Saturday, June 22
    Via Talk Markets
    Here's How Much $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today
    Via Benzinga
    $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.